spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  temozolomide 

 HSMN NewsFeed - 11 Oct 2022
GT Medical Technologies Announces First Patient Enrolled in GESTALT Trial of GammaTile(R) Therapy for Newly Diagnosed Glioblastoma Brain Tumors
Devices Oncology Neurosurgery
 HSMN NewsFeed - 22 Sep 2021
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 21 May 2019
DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Sep 2018
Tocagen Appoints Mohamed Ladha as Vice President to Establish Commercial Organization
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jun 2017
DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jul 2016
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
Devices Oncology
 HSMN NewsFeed - 21 Apr 2016
FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Mar 2016
Lannett Receives FDA Approvals For Two Products
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 1 Mar 2016
FLAG Therapeutics Announces the Granting of Orphan Drug Designation to FLAG-003 in both the US and EU for the Treatment of Glioma
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 11 Feb 2016
Lannett Receives FDA Approval For Temozolomide Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 5 Oct 2015
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
Devices Oncology Regulatory
 HSMN NewsFeed - 11 May 2015
FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma
Devices Oncology FDA
 HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Nov 2013
Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Aug 2013
Teva Pharmaceutical And Perrigo Company Announce The U.S. Launch Of Generic Temozolomide
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 10 Aug 2012
Genentech Study Showed That Adding Avastin to Radiation and Chemotherapy Significantly Extended the Time People with an Aggressive Form of Brain Cancer Lived without Their Disease Worsening
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Feb 2012
Delcath Appoints Industry Veteran Chris Houchins as Senior Vice President of Clinical and Medical Affairs
Devices Drug Delivery Personnel
 HSMN NewsFeed - 6 Sep 2011
DelMar Pharmaceuticals Receives FDA IND Approval to Begin Clinical Trials With A New Brain Cancer Treatment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 May 2011
Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
Devices Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 22 Nov 2010
Paclitaxel Poliglumex (OPAXIO(R)) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2010
Myriad Pharmaceuticals Announces Intent to Focus on Oncology Portfolio
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Aug 2009
Patients Begin Enrolling into Investigator-Sponsored Phase 2 Trial of Antigenics' Oncophage(R) Cancer Vaccine in Newly Diagnosed Glioma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 May 2009
FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Mar 2009
European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 8 Dec 2008
CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Dec 2008
Vion Pharmaceuticals Adds Tanya Lewis to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Nov 2008
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jul 2008
Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2008
Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2008
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2008
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 7 Dec 2007
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Nov 2007
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2007
Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Aug 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jul 2007
Barr Confirms Patent Challenge of TEMODAR(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 3 Jun 2007
Celldex Therapeutics Announces Updated EGFRvIII Vaccine Data in Glioblastoma Multiforme Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2007
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 May 2007
Tapestry Pharmaceuticals Announces Phase II Clinical Program for TPI 287
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2007
Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jan 2007
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7(R) as First-line Therapy for Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane(R) and Temodar(R) as First-Line Therapy for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2006
Gliadel(R) Wafer Clinical Data Presented at Society for Neuro-Oncology Meeting
Biopharmaceuticals Neurosurgery Oncology
 HSMN NewsFeed - 13 Nov 2006
Vion Pharmaceuticals Reaches Midpoint of Patient Accrual to Cloretazine(R) (VNP40101M) Phase III Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2006
Novacea Initiates Phase 1/2 Trial of AQ4N in Glioblastoma Multiforme
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2006
Vion Pharmaceuticals Presents Initial Data From a Phase II Trial of Cloretazine(R) (VNP40101M) in Patients With Relapsed or Refractory Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jul 2006
Aileen Ryan Joins Vion Pharmaceuticals' Senior Management Team
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2006
Jonathan R. Spicehandler, M.D. Retires From Schering-Plough
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 May 2006
Vion Pharmaceuticals Provides Update for Clinical and Preclinical Programs
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Vion Initiates Pivotal Phase II Trial of Single Agent Cloretazine(R) in Elderly Patients with De Novo Poor-Risk Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 32

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 32 additional stories matching:
temozolomide
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.